Eventide Asset Management LLC Makes New Investment in Apogee Therapeutics Inc. $APGE

Eventide Asset Management LLC bought a new position in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 436,015 shares of the company's stock, valued at approximately $32,910,000. Eventide Asset Management LLC owned about 0.64% of Apogee Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FORA Capital LLC acquired a new stake in shares of Apogee Therapeutics in the 4th quarter worth $1,374,000. Marshall Wace LLP increased its stake in shares of Apogee Therapeutics by 622.1% in the 4th quarter. Marshall Wace LLP now owns 50,744 shares of the company's stock worth $3,830,000 after acquiring an additional 43,717 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Apogee Therapeutics by 27.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 80,832 shares of the company's stock worth $6,118,000 after acquiring an additional 17,607 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Apogee Therapeutics by 5.2% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,234,926 shares of the company's stock worth $93,212,000 after acquiring an additional 61,500 shares during the last quarter. Finally, Stifel Financial Corp increased its stake in shares of Apogee Therapeutics by 3.5% in the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company's stock worth $394,000 after acquiring an additional 175 shares during the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,500 shares of the firm's stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $78.71, for a total transaction of $432,905.00. Following the completion of the transaction, the insider directly owned 205,648 shares in the company, valued at $16,186,554.08. This trade represents a 2.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $82.58, for a total value of $1,651,600.00. Following the transaction, the chief executive officer owned 1,132,987 shares of the company's stock, valued at $93,562,066.46. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 76,500 shares of company stock valued at $6,323,295 over the last 90 days. 24.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

APGE has been the subject of a number of recent analyst reports. Citigroup raised their price objective on Apogee Therapeutics from $95.00 to $125.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. Rothschild & Co Redburn initiated coverage on Apogee Therapeutics in a research report on Friday, May 1st. They set a "buy" rating and a $140.00 price objective for the company. Royal Bank Of Canada raised their price objective on Apogee Therapeutics from $82.00 to $97.00 and gave the stock a "sector perform" rating in a research report on Monday, June 8th. Mizuho raised their price objective on Apogee Therapeutics from $105.00 to $110.00 and gave the stock an "outperform" rating in a research report on Monday, March 30th. Finally, Guggenheim raised their price objective on Apogee Therapeutics from $130.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Apogee Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $114.56.

Apogee Therapeutics Trading Down 1.3%

Shares of NASDAQ:APGE opened at $88.33 on Friday. The business has a 50-day moving average price of $84.47 and a 200 day moving average price of $77.33. The company has a market capitalization of $5.47 billion, a price-to-earnings ratio of -20.40 and a beta of 0.62. Apogee Therapeutics Inc. has a 12-month low of $34.34 and a 12-month high of $95.32.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.01. As a group, equities research analysts predict that Apogee Therapeutics Inc. will post -4.45 earnings per share for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.